Investigational Site Number :2500001

Villejuif 94805

0 studies enrolling now · 7 studies all time

What they study most

Breast Cancer Metastatic, Colorectal Cancer, Gastric Cancer, Hepatocellular Carcinoma, Malignant Solid Tumor, Metastatic Neoplasm, Non-small Cell Lung Cancer, Oesophageal Adenocarcinoma, Oesophageal Squamous Cell Carcinoma, Plasma Cell Myeloma, Prostate Cancer, Squamous Cell Carcinoma of Head and Neck

Studies at this site

• Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer — Stopped early
• A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) — Completed
• A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204) — Stopped early
• A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors — Stopped early
• A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors — Completed
• Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients — Completed
• Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies — Stopped early